Home | ALL Hub
Home | Lymphoma Hub
Home | AML Hub
Description: MPN Hub webinar: Treatment sequencing for anemic myelofibrosis, Clinical trial club
Myelofibrosis is associated with a significant reduction in the quality of life of patients and an increased risk of mortality. As treatment options are mainly symptomatic, major treatment goals include reduction of symptoms and improvement of quality of life. While JAK inhibitors provide spleen control and symptom improvement for patients, response to treatment is often lost and there is currently an unmet need for novel therapies to effectively target the disease at the level of the malignant stem cell.
There is an ongoing effort to develop novel approaches with different modes of action to fulfil an unmet need when JAK inhibitors are not enough or fail to halt disease progression. With such progress, it is key that healthcare professionals understand novel targets and the mechanisms of action of new agents and maintain up-to-date knowledge of the role of new agents in the therapeutic landscape.
Luspatercept for the treatment of patients with anemic myelofibrosis
Home | ALL Hub
Home | Lymphoma Hub
Home | AML Hub